৳ 150/unit
Pack: ৳ 1,500
৳ 150/unit
Pack: ৳ 1,500
At a glance
Sotagliflozin is an SGLT1 and SGLT2 inhibitor used as an adjunct to insulin therapy to improve glycemic control in type 1 diabetes mellitus (BMI ≥27 kg/m² with inadequate glycemic control despite optimal insulin therapy).
Indications
- Type 1 diabetes mellitus (BMI ≥27 kg/m², inadequate glycemic control despite optimal insulin therapy)
Pharmacology
Sotagliflozin inhibits both SGLT1 and SGLT2. SGLT1 inhibition reduces intestinal glucose absorption, blunting postprandial glucose spikes. SGLT2 inhibition reduces renal glucose reabsorption in the proximal tubule, increasing urinary glucose excretion and lowering blood glucose levels.
Dosage
Adult Dose (Oral):
- Recommended: 200 mg once daily (before the first meal of the day)
- If additional glycemic control is needed: Increase to 400 mg once daily after at least 3 months
Side effects
Side Effects:
- Hypotension
- Renal impairment
- Hepatic impairment
- Genital mycotic infections
- Urinary tract infections
- Nausea, vomiting, abdominal pain
- Excessive thirst, constant fatigue
- Ketonuria or elevated beta-hydroxybutyrate
- Rapid weight loss
Use in pregnancy
Use in Pregnancy: No data available on use in pregnant women; consult your doctor.
Pregnancy Category: C — always consult a doctor before taking during pregnancy.
Precautions & warnings
- Risk of hypoglycemia with insulin (may require insulin dose reduction)
- Hypotension: Assess volume status in elderly, renal impairment, low systolic BP, patients on diuretics
- eGFR <60: Not recommended to initiate; discontinue if eGFR <45
- Do not use in moderate-severe hepatic impairment
Overdose effects
Multiple doses up to 800 mg/day were well tolerated; in overdose, provide symptomatic supportive treatment; removal by hemodialysis has not been studied.
Storage conditions
Store below 30°C; keep away from light; keep out of reach of children.